ABP 215, CAS 1438851-35-4

Product Description: ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10(4):678-691. /[2]Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17(36):5119-5127.

CAS Number: 1438851-35-4

Molecular Weight: N/A

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: VEGFR

• Artikelnummer: MEXHY-P99476-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99476-5
• Verpackungseinheit: 5mg
• Mengeneinheit: STK
• Konjugat: Unconjugated